Med Reference

---
name: med-reference
description: "Use when correcting a medical or pharmacological misconception, looking up a half-life, dose-response, likelihood-ratio, trial or epidemiological figure, finding the sources, or needing a quick-reference picker — plus the current state of incretin therapeutics and antimicrobial resistance. Companion to the other medicine and pharmacology skills."
---

# Medicine and Pharmacology: What's Live, Misconceptions, Numbers and Concepts, and Sources

> **Part 6 of 6** of the *Fundamentals of Medicine and Pharmacology* reference (plugin `medicine-and-pharmacology-fundamentals`), covering §27–§32. Sibling skills: `med-reading-the-field-physiology-and-clinical-reasoning` (§0–§6), `med-pharmacokinetics-pharmacodynamics-and-interactions` (§7–§12), `med-drug-classes-cardiovascular-anti-infective-and-analgesia` (§13–§15), `med-drug-classes-neuro-endocrine-immunology-and-oncology` (§16–§19), `med-evidence-trials-safety-screening-and-ethics` (§20–§26). Section numbers are shared across the set; a reference written as §N → `skill` points into that sibling skill.
>
> **Currency:** The physiology and pharmacology are stable. Two areas are moving fast. See §27 for incretin therapeutics, and antimicrobial resistance.

> **⚠️ NOT MEDICAL ADVICE, and this matters more here than in any other file in this
> series.** ⚠️ **Nothing here is a diagnosis, a treatment recommendation, or dosing
> guidance. Individual clinical decisions require a licensed clinician who knows your
> history, and no general reference substitutes for that.**
>
> **⚠️ This is pitched where a preclinical survey or an informed-patient reference sits:
> the concepts that let you understand what medicine is doing and evaluate claims about
> it.** ⚠️ **It deliberately contains no dosing tables, no specific regimens, and no
> operational detail.**
>
> **Complements an organic-chemistry reference (drug molecules and metabolism), a
> statistics-adjacent reference (trial methodology), and a speaking-and-influence reference
> (§20 → `med-evidence-trials-safety-screening-and-ethics`'s evidence-quality reasoning is the same skill).**
>
> **⚠️ GOTCHA** boxes mark where clinical intuition — including clinicians' intuition — is
> reliably wrong.
>
> **The three ideas that organize this document:**
> 1. **⚠️ A TEST RESULT IS NOT A DIAGNOSIS** (§6 → `med-reading-the-field-physiology-and-clinical-reasoning`). **The probability that a positive test
>    means disease depends on how likely disease was beforehand. This single Bayesian fact
>    is the most useful thing in clinical medicine and the most consistently misunderstood
>    by patients and clinicians alike.**
> 2. **⚠️ EVERY DRUG IS A POISON AT SOME DOSE, AND EVERY EFFECT HAS A COST** (§9 → `med-pharmacokinetics-pharmacodynamics-and-interactions`, §12 → `med-pharmacokinetics-pharmacodynamics-and-interactions`).
>    **There are no side effects — only effects, some of which you wanted. The therapeutic
>    question is always a ratio, never an absolute.**
> 3. **⚠️ MOST OF WHAT DETERMINES HEALTH HAPPENS OUTSIDE CLINICAL MEDICINE** (§25 → `med-evidence-trials-safety-screening-and-ethics`).
>    **Sanitation, nutrition, income, housing and vaccination did more for life expectancy
>    than the entire therapeutic pharmacopoeia, and clinical medicine's share of health
>    outcomes is smaller than its share of spending.**

---

## §27. What's Live — checked August 2026

### 27.1 ⚠️ Incretin therapeutics: a class that outgrew its indication
**⚠️ §17 → `med-drug-classes-neuro-endocrine-immunology-and-oncology`'s area being reshaped, and it is the clearest current illustration of §20 → `med-evidence-trials-safety-screening-and-ethics`'s
surrogate-versus-outcome distinction working in the right direction.**

- **⚠️ THE EFFICACY STAIRCASE, as summarized in the trade and academic literature**:
  ⚠️ **semaglutide, a single GLP-1 receptor agonist, established roughly 15% average weight
  loss in pivotal obesity trials; tirzepatide, adding GIP receptor agonism, raised that to
  around 21%; and triple agonists in development are reported above 28%.**
- **⚠️ ORAL FORMULATIONS ARRIVED.** ⚠️ **Two pivotal phase 3 trials were published in
  September 2025: ATTAIN-1 evaluated orforglipron in 3,127 adults over 72 weeks with mean
  weight loss of 11.2%, and OASIS-4 studied oral semaglutide 25 mg in 307 adults over 64
  weeks with mean weight loss of 13.6%.** ⚠️ **An oral semaglutide product for weight
  management became available in January 2026.**
  ⚠️ **The formulation problem is genuinely interesting pharmacology (§7 → `med-pharmacokinetics-pharmacodynamics-and-interactions`): semaglutide is a
  large peptide, and oral delivery uses an absorption enhancer to get it across the gut
  wall at all.**
- **⚠️ THE INDICATIONS EXPANDED BEYOND WEIGHT AND GLUCOSE, which is the substantive
  point.** ⚠️ **In the phase 3 ESSENCE trial, semaglutide produced resolution of
  steatohepatitis without worsening fibrosis in 62.9% of patients with biopsy-confirmed
  MASH versus 34.3% with placebo, with FDA accelerated approval for that indication in
  August 2025.** ⚠️ **Reported cardiovascular benefits include a 14% reduction in major
  adverse cardiovascular events.** ⚠️ **Knee osteoarthritis pain outcomes also improved.**

> **⚠️ GOTCHA — this is a class where the honest caveats are as important as the
> headlines.** ⚠️ **The trials are largely industry-sponsored (§21 → `med-evidence-trials-safety-screening-and-ethics`), and much accessible
> coverage comes from pharmacy benefit managers, prescription-discount companies and
> conference reporting rather than from independent analysis.**
> ⚠️ **Gastrointestinal adverse events are consistent across the class; the oral trials
> reported five mild pancreatitis cases with orforglipron and dysesthesia with oral
> semaglutide.** ⚠️ **Longer-term safety follows §12 → `med-pharmacokinetics-pharmacodynamics-and-interactions`'s rule — a class this new, used this
> widely, will have its full profile characterized only in post-marketing surveillance.**
> **⚠️ Lean body mass preservation, durability after discontinuation, cost and access
> remain genuinely open questions**, ⚠️ **and one review notes GLP-1 use in the US rose
> roughly 700% over four years to 2023, which is an adoption curve outpacing the long-term
> evidence.**

**⚠️ Why it matters conceptually**: ⚠️ **these agents are increasingly chosen for OUTCOME
benefits — cardiovascular events, liver histology — rather than for the surrogate they were
designed to move.** ⚠️ **That is §20 → `med-evidence-trials-safety-screening-and-ethics`'s distinction operating correctly, and it is rarer than
it should be.**

### 27.2 ⚠️ Antimicrobial resistance: the problem that gets worse while nothing happens
**⚠️ §14 → `med-drug-classes-cardiovascular-anti-infective-and-analgesia`'s structural problem, and the sharpest contrast with §27.1 in this file.**

- **⚠️ THE SCALE.** ⚠️ **WHO states that approximately 1 in 6 laboratory-confirmed bacterial
  infections worldwide were resistant to antibiotics in 2023.** ⚠️ **The 2025 GLASS report
  drew on more than 23 million bacteriologically confirmed cases reported by 104 countries,
  providing estimates across 93 infection-pathogen-antibiotic combinations and tracking
  trends for 16 of them from 2018 to 2023.**
- ⚠️ **Gram-negative organisms are the acute concern, with rising resistance to carbapenems
  and fluoroquinolones — and low- and middle-income countries bear a higher burden through
  weaker health systems and limited diagnostic capacity.**
- **⚠️ WHO'S OWN CHARACTERIZATION IS BLUNT**: ⚠️ **"the world faces an antimicrobial research
  and development crisis, with few new medicines in the pipeline."** ⚠️ **The Global Action
  Plan on AMR has been updated for 2026–2036.**
- **⚠️ THE PIPELINE ASSESSMENT.** ⚠️ **The Access to Medicine Foundation's 2026 AMR
  Benchmark, reviewing 25 companies, found continued CONTRACTION among the seven large
  research-based companies, with small and medium enterprises driving innovation for
  critical- and high-priority pathogens.** ⚠️ **Its overall conclusion is that industry-wide
  efforts "are being outpaced by drug resistance."**

> **⚠️ GOTCHA — this is a MARKET FAILURE, not a science failure, and the economics are
> perverse in a specific way.** ⚠️ **A successful new antibiotic should be used as little as
> possible and reserved for resistant infections (§14 → `med-drug-classes-cardiovascular-anti-infective-and-analgesia`'s stewardship) — which means the
> better it is, the less revenue it generates.** **⚠️ No other drug class has that property,
> and it is why conventional market incentives cannot fund antibiotic development.**
> ⚠️ **The consequences are visible in the reporting: a company terminating its sole
> pipeline project and dropping out of the benchmark entirely, and analysis noting expected
> pipeline decline as late-stage funding tapers.**
> **⚠️ There is also a substantive critique that pipeline expansion alone is not the
> answer** — ⚠️ **infectious disease specialists quoted argue that producing more drugs
> within the same class does little for genuinely resistant organisms, and that innovation
> has been "predominantly incremental," built on old scaffolds rather than novel
> mechanisms.**

**⚠️ What is actually being tried**: ⚠️ **WHO published new target product profiles in March
2026 defining minimum and preferred characteristics for urgently needed antibacterials;
⚠️ pull incentives such as market entry rewards and subscription models attempt to decouple
revenue from volume; ⚠️ and alternative modalities — phage therapy, antimicrobial peptides,
CRISPR-based approaches — are under investigation with real translational obstacles.**
**⚠️ And the unglamorous interventions remain the highest-value ones**: ⚠️ **infection
prevention, vaccination, diagnostics that let clinicians avoid empirical broad-spectrum
treatment, surveillance, and stewardship** (§14 → `med-drug-classes-cardiovascular-anti-infective-and-analgesia`, §25 → `med-evidence-trials-safety-screening-and-ethics`).
**⚠️ Sourcing note: this section rests on WHO's own fact sheet and GLASS report and on the
Access to Medicine Foundation benchmark — the latter being an independent nonprofit rather
than an industry body, which is why I have used its pipeline assessment.**

---

## §28. Misconceptions

| Misconception | Correction |
|---|---|
| A positive test means you have it | ⚠️ **Depends on pre-test probability. Often it doesn't** (§6 → `med-reading-the-field-physiology-and-clinical-reasoning`) |
| A very accurate test is reliable in screening | ⚠️ **Low prevalence swamps it with false positives** (§6 → `med-reading-the-field-physiology-and-clinical-reasoning`, §24 → `med-evidence-trials-safety-screening-and-ethics`) |
| Sensitivity tells you what a positive means | ⚠️ **That's PPV, and it depends on prevalence** (§6 → `med-reading-the-field-physiology-and-clinical-reasoning`) |
| Diagnosis comes from tests | ⚠️ **Mostly from the history** (§5 → `med-reading-the-field-physiology-and-clinical-reasoning`) |
| Feeling fine means healthy | ⚠️ **Organ reserve masks substantial damage** (§2 → `med-reading-the-field-physiology-and-clinical-reasoning`) |
| Side effects are a separate category | ⚠️ **They're just effects you didn't want** (§12 → `med-pharmacokinetics-pharmacodynamics-and-interactions`) |
| Natural products don't interact | ⚠️ **St John's wort induces CYP enzymes potently** (§10 → `med-pharmacokinetics-pharmacodynamics-and-interactions`) |
| A more potent drug is a better drug | ⚠️ **Potency is dose, not effect. Different axis** (§9 → `med-pharmacokinetics-pharmacodynamics-and-interactions`) |
| Half-life tells you when it's gone | ⚠️ **~4–5 half-lives to steady state and to washout** (§7 → `med-pharmacokinetics-pharmacodynamics-and-interactions`) |
| Oral and IV doses should match | ⚠️ **First-pass metabolism** (§7 → `med-pharmacokinetics-pharmacodynamics-and-interactions`) |
| Physical dependence is addiction | ⚠️ **Three different things. Conflating harms both ways** (§15 → `med-drug-classes-cardiovascular-anti-infective-and-analgesia`) |
| Stopping a drug is always safe | ⚠️ **Receptor upregulation causes rebound. Some need tapering** (§8 → `med-pharmacokinetics-pharmacodynamics-and-interactions`, §16 → `med-drug-classes-neuro-endocrine-immunology-and-oncology`) |
| Antibiotics help with a bad cold | ⚠️ **Viral. No benefit, and drives resistance** (§14 → `med-drug-classes-cardiovascular-anti-infective-and-analgesia`) |
| Always finish the antibiotic course | ⚠️ **Being revised for many indications — ask the prescriber** (§14 → `med-drug-classes-cardiovascular-anti-infective-and-analgesia`) |
| Depression is a chemical imbalance | ⚠️ **Oversimplified and unsupported. The drugs still work** (§16 → `med-drug-classes-neuro-endocrine-immunology-and-oncology`) |
| A drug improving a lab value helps you | ⚠️ **Surrogate ≠ outcome. See CAST** (§13 → `med-drug-classes-cardiovascular-anti-infective-and-analgesia`, §20 → `med-evidence-trials-safety-screening-and-ethics`) |
| "Reduces risk 50%" is impressive | ⚠️ **Ask for absolute risk and NNT** (§20 → `med-evidence-trials-safety-screening-and-ethics`) |
| Approved means fully characterized | ⚠️ **Rare harms appear only post-marketing** (§12 → `med-pharmacokinetics-pharmacodynamics-and-interactions`, §22 → `med-evidence-trials-safety-screening-and-ethics`) |
| Biosimilars are generics | ⚠️ **You can't copy a large protein exactly** (§18 → `med-drug-classes-neuro-endocrine-immunology-and-oncology`) |
| Five-year survival measures progress | ⚠️ **Lead time and length bias. Use mortality** (§19 → `med-drug-classes-neuro-endocrine-immunology-and-oncology`, §24 → `med-evidence-trials-safety-screening-and-ethics`) |
| Early detection is always good | ⚠️ **Only if earlier treatment changes outcome** (§24 → `med-evidence-trials-safety-screening-and-ethics`) |
| Overdiagnosis means misdiagnosis | ⚠️ **The diagnosis is correct — that's what makes it insidious** (§24 → `med-evidence-trials-safety-screening-and-ethics`) |
| More screening saves more lives | ⚠️ **Needs a randomized mortality comparison to know** (§24 → `med-evidence-trials-safety-screening-and-ethics`) |
| Medical error is bad doctors | ⚠️ **System failures. Blame destroys reporting** (§23 → `med-evidence-trials-safety-screening-and-ethics`) |
| Healthcare drives life expectancy | ⚠️ **Sanitation, nutrition, vaccination did more** (§25 → `med-evidence-trials-safety-screening-and-ethics`) |
| Target the high-risk group | ⚠️ **Most cases come from the large modest-risk group** (§25 → `med-evidence-trials-safety-screening-and-ethics`) |
| The antibiotic pipeline is a science problem | ⚠️ **A market failure — success means low sales** (§27.2) |

---

## §29. Numbers and Concepts

```
⚠️ ⚠️ PPV depends on PREVALENCE; sensitivity and specificity
   do not
⚠️ ⚠️ Worked example  ⚠️ 99%/99% test, 1-in-10,000 disease →
   ⚠️ PPV under 1%
⚠️ Likelihood ratio near 1  ⚠️ the test told you nothing
⚠️ ⚠️ Steady state / washout  ⚠️ ~4-5 half-lives
⚠️ Bioavailability  ⚠️ IV = 100% by definition
⚠️ Zero-order kinetics  ⚠️ ethanol, phenytoin — constant AMOUNT
⚠️ ⚠️ NNT  ⚠️ = 1 ÷ absolute risk reduction
⚠️ Wilson-Jungner  ⚠️ the treatment criterion is the neglected one
⚠️ ⚠️ Semaglutide obesity trials  ⚠️ ~15% mean weight loss
⚠️ ⚠️ Tirzepatide (dual GLP-1/GIP)  ⚠️ ~21%
⚠️ Triple agonists in development  ⚠️ reported >28%
⚠️ ATTAIN-1 (orforglipron, oral)  ⚠️ 11.2%, n=3,127, 72 wk
⚠️ OASIS-4 (oral semaglutide 25mg)  ⚠️ 13.6%, n=307, 64 wk
⚠️ ESSENCE (MASH)  ⚠️ 62.9% resolution vs 34.3% placebo
⚠️ GLP-1 cardiovascular  ⚠️ ~14% MACE reduction
⚠️ ⚠️ AMR  ⚠️ ~1 in 6 confirmed bacterial infections resistant
   (2023, WHO)
⚠️ GLASS 2025 report  ⚠️ >23 million confirmed cases, 104 countries
⚠️ ⚠️ WHO GAP-AMR  ⚠️ 2026-2036
⚠️ 2026 AMR Benchmark  ⚠️ 25 companies · ⚠️ large-company
   pipelines CONTRACTING · SMEs driving priority-pathogen work
```

---

## §30. Sources

| Source | Why |
|---|---|
| **Rang & Dale's *Pharmacology*; Katzung's *Basic & Clinical Pharmacology*** | ⚠️ **§7–§12 → `med-pharmacokinetics-pharmacodynamics-and-interactions`, the standards** |
| **Goodman & Gilman's *The Pharmacological Basis of Therapeutics*** | The reference work |
| **Guyton & Hall, *Textbook of Medical Physiology*** | §2 → `med-reading-the-field-physiology-and-clinical-reasoning` |
| **Robbins, *Pathologic Basis of Disease*** | §4 → `med-reading-the-field-physiology-and-clinical-reasoning` |
| **Cochrane Library** | ⚠️ **§20 → `med-evidence-trials-safety-screening-and-ethics` — systematic reviews, free abstracts** |
| **BMJ *Clinical Evidence* tradition; *Testing Treatments* (free online)** | ⚠️ **§20–§21 → `med-evidence-trials-safety-screening-and-ethics`, accessible and excellent** |
| **Gigerenzer on risk communication** | ⚠️ **§6 → `med-reading-the-field-physiology-and-clinical-reasoning`, §20 → `med-evidence-trials-safety-screening-and-ethics` — natural frequencies fix the base rate error** |
| **Welch, *Should I Be Tested for Cancer?* / *Overdiagnosed*** | ⚠️ **§24 → `med-evidence-trials-safety-screening-and-ethics`** |
| **Rose, *The Strategy of Preventive Medicine*** | ⚠️ **§25 → `med-evidence-trials-safety-screening-and-ethics` — short and foundational** |
| **WHO fact sheets and GLASS reports** | ⚠️ **§14 → `med-drug-classes-cardiovascular-anti-infective-and-analgesia`, §27.2 — primary and free** |
| ***To Err Is Human*; *Crossing the Quality Chasm*** | §23 → `med-evidence-trials-safety-screening-and-ethics` |
| **Beauchamp & Childress, *Principles of Biomedical Ethics*** | §26 → `med-evidence-trials-safety-screening-and-ethics` |

---

## §31. Quick Reference

### 31.1 Picker
| Question | Where |
|---|---|
| What does my positive test mean? | ⚠️ **Ask about pre-test probability first** (§6 → `med-reading-the-field-physiology-and-clinical-reasoning`) |
| Should I get this test? | ⚠️ **Will the result change what happens?** (§6 → `med-reading-the-field-physiology-and-clinical-reasoning`, §24 → `med-evidence-trials-safety-screening-and-ethics`) |
| Is this screening worth it? | ⚠️ **Does earlier treatment change mortality?** (§24 → `med-evidence-trials-safety-screening-and-ethics`) |
| How good is this drug? | ⚠️ **Absolute risk reduction and NNT, not relative** (§20 → `med-evidence-trials-safety-screening-and-ethics`) |
| Is this trial result trustworthy? | ⚠️ **Registered endpoint? ITT? Who funded it?** (§21 → `med-evidence-trials-safety-screening-and-ethics`) |
| Why does this drug take weeks? | ⚠️ **Half-lives to steady state, or downstream adaptation** (§7 → `med-pharmacokinetics-pharmacodynamics-and-interactions`, §16 → `med-drug-classes-neuro-endocrine-immunology-and-oncology`) |
| Can I stop this medication? | ⚠️ **Ask the prescriber — some need tapering** (§8 → `med-pharmacokinetics-pharmacodynamics-and-interactions`) |
| Why did the dose change? | ⚠️ **Usually renal or hepatic function** (§7 → `med-pharmacokinetics-pharmacodynamics-and-interactions`, §11 → `med-pharmacokinetics-pharmacodynamics-and-interactions`) |
| Do I need an antibiotic? | ⚠️ **Not for viral illness. That's the prescriber's call** (§14 → `med-drug-classes-cardiovascular-anti-infective-and-analgesia`) |
| Is a supplement safe with my meds? | ⚠️ **Tell the prescriber. "Natural" means nothing here** (§10 → `med-pharmacokinetics-pharmacodynamics-and-interactions`) |
| Is this survival statistic meaningful? | ⚠️ **Five-year survival is biased. Ask for mortality** (§19 → `med-drug-classes-neuro-endocrine-immunology-and-oncology`, §24 → `med-evidence-trials-safety-screening-and-ethics`) |
| Anything personal or urgent | ⚠️ **See a clinician. This file cannot help you** (§1 → `med-reading-the-field-physiology-and-clinical-reasoning`) |

### 31.2 Evaluating a medical claim
- [ ] ⚠️ **Outcome that matters to patients, or a surrogate?** (§20 → `med-evidence-trials-safety-screening-and-ethics`)
- [ ] ⚠️ **Absolute risk reduction stated, and NNT?** (§20 → `med-evidence-trials-safety-screening-and-ethics`)
- [ ] ⚠️ **Compared against what — placebo, or best current care?** (§21 → `med-evidence-trials-safety-screening-and-ethics`)
- [ ] Randomized, and was allocation concealed? (§21 → `med-evidence-trials-safety-screening-and-ethics`)
- [ ] ⚠️ **Was the endpoint pre-registered, or switched?** (§21 → `med-evidence-trials-safety-screening-and-ethics`)
- [ ] Intention-to-treat analysis? (§21 → `med-evidence-trials-safety-screening-and-ethics`)
- [ ] ⚠️ **Do the trial participants resemble the patient?** (§21 → `med-evidence-trials-safety-screening-and-ethics`)
- [ ] ⚠️ **Harms reported as carefully as benefits?** (§12 → `med-pharmacokinetics-pharmacodynamics-and-interactions`, §20 → `med-evidence-trials-safety-screening-and-ethics`)
- [ ] Who funded it, and who wrote it? (§21 → `med-evidence-trials-safety-screening-and-ethics`)
- [ ] ⚠️ **For a test: what happens to pre-test probability?** (§6 → `med-reading-the-field-physiology-and-clinical-reasoning`)
- [ ] ⚠️ **For screening: mortality benefit, and overdiagnosis estimated?** (§24 → `med-evidence-trials-safety-screening-and-ethics`)

---

## §32. Method

**§1–§26 → `med-reading-the-field-physiology-and-clinical-reasoning`, `med-pharmacokinetics-pharmacodynamics-and-interactions`, `med-drug-classes-cardiovascular-anti-infective-and-analgesia`, `med-drug-classes-neuro-endocrine-immunology-and-oncology`, `med-evidence-trials-safety-screening-and-ethics` rests on standard preclinical and clinical curricula** — **ADME, receptor
pharmacology, dose-response, the Bayesian structure of diagnostic testing, the evidence
hierarchy, the documented trial pathologies, Wilson-Jungner, and Rose's prevention
paradox.** ⚠️ **None needed verification; the pharmacokinetic principles are decades old and
the base rate problem is arithmetic.**

**⚠️ On scope: I have deliberately included no doses, no regimens and no self-treatment
guidance.** ⚠️ **That is not padding the disclaimer — the concepts here are genuinely
useful for evaluating medical claims, and they are useless and dangerous as a substitute
for a clinician who knows your history.** ⚠️ **If something in this file made you think
about your own care, the correct next step is a conversation with a clinician, and §31.1 is
written to help you have that conversation rather than to replace it.**

**Two searches were run in August 2026**, on **incretin therapeutics** and **antimicrobial
resistance** — ⚠️ **chosen deliberately as a contrasting pair: the fastest-moving area in
therapeutics and the slowest, and the contrast between them is itself the lesson about how
pharmaceutical incentives allocate effort.**

**Confidence.** **High** in §6 → `med-reading-the-field-physiology-and-clinical-reasoning`, which is the section I'd most want read by anyone.
⚠️ **The worked example — a 99%/99% test in a 1-in-10,000 population yielding a positive
predictive value under 1% — is arithmetic, not opinion, and it changes how a person reads
every test result they will ever receive.** ⚠️ **Gigerenzer's finding that presenting this
as NATURAL FREQUENCIES rather than percentages dramatically improves reasoning, including
among clinicians, is why I wrote it out in counts.**
**⚠️ §24 → `med-evidence-trials-safety-screening-and-ethics` follows directly from §6 → `med-reading-the-field-physiology-and-clinical-reasoning` and is where the arithmetic becomes policy — overdiagnosis
is the hardest concept here precisely because the diagnosis is CORRECT, and there is no
constituency for stopping a screening programme.**
**⚠️ §20 → `med-evidence-trials-safety-screening-and-ethics`'s absolute-versus-relative risk distinction is the most practically useful thing
for reading any health news story.**

**High** on §27.1's trial figures, which come from peer-reviewed publications and phase 3
trial reports: ⚠️ **ATTAIN-1's 11.2% in 3,127 adults, OASIS-4's 13.6%, ESSENCE's 62.9%
versus 34.3% for MASH resolution.**
⚠️ **I have flagged that much accessible coverage comes from pharmacy benefit managers,
discount-card companies and conference reporting — commercially interested sources — and
that §12 → `med-pharmacokinetics-pharmacodynamics-and-interactions`'s rule applies with full force to a drug class adopted this fast.**

**High** on §27.2, anchored on WHO's own fact sheet and GLASS report and on the Access to
Medicine Foundation's benchmark — ⚠️ **an independent nonprofit rather than an industry
body, which is why I used its pipeline finding that large-company pipelines are
contracting.**
⚠️ **The market-failure framing is the part worth carrying: a good antibiotic should be used
as little as possible, so the better it is, the less it earns.** **⚠️ No other drug class
has that property, and it explains why this problem persists while §27.1's does not.**